Release Date: 11-Feb-2025
In 2024, Roche’s Hemlibra, a bispecific antibody for hemophilia A, achieved sales of over US$ 4.9 billion, marking an 8.6% increase from US$ 4.5 billion in 2023. This growth solidifies its position as the highest-selling bispecific antibody globally and Roche’s top-selling oncology drug. Hemlibra’s strong market performance is driven by its efficacy, widespread adoption, and increasing demand for innovative hemophilia treatments. Its consistent sales growth highlights its dominance in the bispecific antibody segment and its critical role in Roche’s pharmaceutical revenue.
For Global Bispecific Antibodies Report Sample Contact [email protected]